More importantly, HK2 inhibition by the HDAC inhibitor panobinostat remarkably ameliorated the cisplatin resistance of B-cell lymphoma cell lines [30]. This evidence concerns the gene HDAC9 and B-cell non-Hodgkin lymphoma.